IA Mayer

446 total citations
25 papers, 297 citations indexed

About

IA Mayer is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, IA Mayer has authored 25 papers receiving a total of 297 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pulmonary and Respiratory Medicine, 20 papers in Oncology and 9 papers in Molecular Biology. Recurrent topics in IA Mayer's work include Advanced Breast Cancer Therapies (19 papers), Cancer Treatment and Pharmacology (14 papers) and HER2/EGFR in Cancer Research (9 papers). IA Mayer is often cited by papers focused on Advanced Breast Cancer Therapies (19 papers), Cancer Treatment and Pharmacology (14 papers) and HER2/EGFR in Cancer Research (9 papers). IA Mayer collaborates with scholars based in United States, France and Switzerland. IA Mayer's co-authors include Dejan Juric, Aditya Bardia, R Moroose, Joyce O’Shaughnessy, Jennifer R. Diamond, Linda T. Vahdat, Kevin Kalinsky, Sara M. Tolaney, David M. Goldenberg and Vandana G. Abramson and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

IA Mayer

25 papers receiving 295 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
IA Mayer United States	9	236	170	88	66	50	25	297
Tong Luo United States	5	225 1.0×	204 1.2×	119 1.4×	63 1.0×	65 1.3×	10	312
Lori Marini United States	4	127 0.5×	95 0.6×	58 0.7×	71 1.1×	20 0.4×	10	193
Markéta Palácová Czechia	8	135 0.6×	62 0.4×	104 1.2×	92 1.4×	23 0.5×	28	254
M. Campone France	8	128 0.5×	86 0.5×	79 0.9×	44 0.7×	32 0.6×	21	217
Elisa Minenza Italy	9	182 0.8×	117 0.7×	59 0.7×	31 0.5×	17 0.3×	12	245
Mengxi Ge China	8	144 0.6×	183 1.1×	97 1.1×	108 1.6×	30 0.6×	15	281
Danai Fimereli Belgium	7	211 0.9×	67 0.4×	63 0.7×	140 2.1×	15 0.3×	10	294
Claudette Falato Spain	10	161 0.7×	78 0.5×	78 0.9×	107 1.6×	14 0.3×	20	261
Sheida Hayati United States	4	94 0.4×	188 1.1×	141 1.6×	98 1.5×	21 0.4×	13	298
Lingzhu Wen China	10	181 0.8×	96 0.6×	153 1.7×	165 2.5×	21 0.4×	24	341

Countries citing papers authored by IA Mayer

Since Specialization

Citations

This map shows the geographic impact of IA Mayer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by IA Mayer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites IA Mayer more than expected).

Fields of papers citing papers by IA Mayer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by IA Mayer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by IA Mayer. The network helps show where IA Mayer may publish in the future.

Co-authorship network of co-authors of IA Mayer

This figure shows the co-authorship network connecting the top 25 collaborators of IA Mayer. A scholar is included among the top collaborators of IA Mayer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with IA Mayer. IA Mayer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

O’Shaughnessy, Joyce, Adam Brufsky, Hope S. Rugo, et al.. (2021). 258P Analysis of patients (pts) without an initial triple-negative breast cancer (TNBC) diagnosis (Dx) in the phase III ASCENT study of sacituzumab govitecan (SG) in brain metastases-negative (BMNeg) metastatic TNBC (mTNBC). Annals of Oncology. 32. S473–S474. 2 indexed citations

Kalinsky, Kevin, Jennifer R. Diamond, Linda T. Vahdat, et al.. (2020). Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial. Annals of Oncology. 31(12). 1709–1718. 111 indexed citations

Rugo, HS, Claudine Isaacs, IA Mayer, et al.. (2019). Abstract PD2-12: Palbociclib in combination with fulvestrant or tamoxifen as treatment for hormone receptor positive (HR+) metastatic breast cancer (MBC) with prior chemotherapy for advanced disease (TBCRC 035) A phase II study with pharmacodynamics markers. Cancer Research. 79(4_Supplement). PD2–12. 1 indexed citations

Kalinsky, Kevin, SJ Isakoff, SM Tolaney, et al.. (2019). Abstract P2-11-01: Safety and efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) as ≥3rd-line therapeutic option for treatment-refractory HER2-negative metastatic breast cancer (HER2Neg mBC). Cancer Research. 79(4_Supplement). P2–11. 3 indexed citations

Juric, Dejan, Eva Ciruelos, Gábor Rubovszky, et al.. (2019). Abstract GS3-08: Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the phase III SOLAR-1 trial. Cancer Research. 79(4_Supplement). GS3–8. 45 indexed citations

Bardia, Aditya, Linda T. Vahdat, Jennifer R. Diamond, et al.. (2018). Abstract GS1-07: Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate, as ≥3rd-line therapeutic option for patients with relapsed/refractory metastatic triple-negative breast cancer (mTNBC): efficacy results. Cancer Research. 78(4_Supplement). GS1–7. 12 indexed citations

Formisano, Luigi, Yao Lu, Ariella B. Hanker, et al.. (2018). Abstract GS6-05: Gain-of-function kinase library screen identifies FGFR1 amplification as a mechanism of resistance to antiestrogens and CDK4/6 inhibitors in ER+ breast cancer. Cancer Research. 78(4_Supplement). GS6–5. 11 indexed citations

Juric, Dejan, A. Gonçalves, Erika Hamilton, et al.. (2018). Abstract P5-21-06: Alpelisib plus letrozole in estrogen receptor-Positive (ER+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (aBC): Safety and preliminary efficacy analysis from a phase 1b trial. Cancer Research. 78(4_Supplement). P5–21. 1 indexed citations

Formisano, Luigi, et al.. (2018). Abstract PD4-07: Genenomic landscape of breast cancers with FGFR1 amplification and FGFR1/CCND1 co-amplification revealed by targeted capture next generation sequencing. Cancer Research. 78(4_Supplement). PD4–7. 1 indexed citations

10.

Kalinsky, Kevin, Codruța Chiuzan, Amy Tiersten, et al.. (2018). Abstract OT3-05-09: A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer (Maintain trial). Cancer Research. 78(4_Supplement). OT3–5. 3 indexed citations

11.

Münster, Pamela N., Roohi Ismail‐Khan, Laura García‐Estévez, et al.. (2017). Abstract P4-22-18: Phase Ib safety, efficacy, and molecular analysis of ribociclib (LEE011) plus letrozole for the treatment of ER+, HER2– advanced breast cancer. Cancer Research. 77(4_Supplement). P4–22. 4 indexed citations

12.

Juric, Dejan, Roohi Ismail‐Khan, Mario Campone, et al.. (2016). Abstract P3-14-01: Phase Ib/II study of ribociclib and alpelisib and letrozole in ER+, HER2– breast cancer: Safety, preliminary efficacy and molecular analysis. Cancer Research. 76(4_Supplement). P3–14. 30 indexed citations

13.

Balko, Justin M., Mellissa Hicks, D. Solit, et al.. (2016). Abstract P3-07-41: Genomic alterations indicative of a luminal A subtype associate with clinical benefit to buparlisib and letrozole in endocrine-resistant ER+/HER2– metastatic breast cancer. Cancer Research. 76(4_Supplement). P3–7. 2 indexed citations

14.

Bardia, Aditya, Krishnaraju Venkatesan, D Robinson, et al.. (2015). 1977 Synergy of LCL161, an antagonist of inhibitor of apoptosis proteins (IAPs), with paclitaxel in a gene expression signature-enriched cohort of triple-negative breast cancer (TNBC). European Journal of Cancer. 51. S326–S326. 3 indexed citations

15.

Mayer, IA, Justin M. Balko, SJ Isakoff, et al.. (2012). Abstract P6-10-05: SU2C Phase 1b Trial of Dual PI3K/ mTOR Inhibitor BEZ235 with Letrozole in ER+/HER2− Metastatic Breast Cancer (MBC). Cancer Research. 72(24_Supplement). P6–10. 1 indexed citations

16.

Mayer, IA, et al.. (2012). Abstract P2-14-04: A Phase Ib Dose Escalation Trial of RO4929097 (a γ-secretase inhibitor) in Combination with Exemestane in Patients with ER + Metastatic Breast Cancer.. Cancer Research. 72(24_Supplement). P2–14. 10 indexed citations

17.

Tolaney, SM, Howard A. Burris, Elaina M. Gartner, et al.. (2011). P1-17-02: A Phase 1/2 Study of SAR245408 (S08) in Combination with Trastuzumab (T) or Paclitaxel (P) and T in Patients with HER2+ Metastatic Breast Cancer (MBC) Who Progressed on a Previous T-Based Regimen.. Cancer Research. 71(24_Supplement). P1–17. 1 indexed citations

18.

Ligibel, JA, HJ Burstein, KD Miller, et al.. (2011). OT3-02-04: TBCRC 012: ABCDE, a Phase II Randomized Study of Adjuvant Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise after Preoperative Chemotherapy for Breast Cancer.. Cancer Research. 71(24_Supplement). OT3–2. 3 indexed citations

19.

Mayer, IA, Julie Means‐Powell, Yu Shyr, et al.. (2011). PD09-06: Phase II Trial of RAD001 (Everolimus), an mTOR Inhibitor, with Weekly Cisplatin and Paclitaxel in Patients with HER2−Negative Metastatic Breast Cancer (MBC).. Cancer Research. 71(24_Supplement). PD09–6. 4 indexed citations

20.

Mayer, IA, Howard A. Burris, Johanna C. Bendell, et al.. (2009). A Phase Ib Trial of RAD001, an mTOR Inhibitor, with Weekly Cisplatin and Paclitaxel in Patients with HER2-Negative Metastatic Breast Cancer.. Cancer Research. 69(24_Supplement). 3093–3093. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact